Tempus AI Scoops Up Personalis For $1.5 Billion; But Shares Dive
Tempus AI moves to acquire cancer-tech firm Personalis in a high-stakes stock deal, triggering an immediate downturn in share prices for both companies.
- Intelligence Anchor: Tempus AI Scoops Up Personalis For $1.5 Billion; But Shares Dive
- Core Takeaway: Tempus AI moves to acquire cancer-tech firm Personalis in a high-stakes stock deal, triggering an immediate downturn in share prices for both companies.
- Signal Velocity: 5 score across 7 independent media sources and 7 indexed articles.
- Forecast Model: Story predicted to decelerate within 24h.
The coverage curve
How fast coverage is spreading — measured hourly from article rate × source diversity. How this works →
The story so far
Tempus AI has announced an agreement to acquire Personalis, a cancer genomics and monitoring firm. The deal aims to integrate molecular residual disease technology directly into the Tempus AI precision oncology platform.
Coverage from outlets including Barron's, Reuters, Bloomberg, and Quartz emphasizes the transaction's valuation and the subsequent decline in stock prices for both entities. Reports specify the deal as a stock-based transaction, though valuation estimates vary between $1.5 billion and $1.7 billion across different sources.
Market observers are monitoring the integration of these two technologies and the sustained performance of the involved stocks following the acquisition announcement.
Synthesized by headlinez.news from the headlines below under a strict no-invention contract. ✓ fact-checked: all claims supported by sources Updated 92d ago.
Coverage (7)
- Tempus AI is acquiring cancer-monitoring firm Personalis in a $1.5 billion stock deal qz.com · 94d ago
- Tempus AI to Buy Cancer-Tech Firm Personalis For $1.7 Billion Bloomberg.com · 94d ago
- Tempus buys out cancer genomics partner Personalis in $1.5 billion deal Fierce Biotech · 94d ago
- Tempus to Acquire Personalis, More Tightly Integrating Molecular Residual Disease (MRD) into Its AI-Enabled Precision Oncology Platform Business Wire · 94d ago
- Tempus AI Buys Personalis for $1.5 Billion, and Both Stocks Sink Barron's · 94d ago
- Tempus to buy cancer test maker Personalis for $1.5 billion Reuters · 94d ago
- Tempus AI Scoops Up Personalis For $1.5 Billion; But Shares Dive Investor's Business Daily · 94d ago
The obvious questions
What is the primary goal of this acquisition?
The acquisition is intended to integrate Personalis's molecular residual disease technology into Tempus AI's precision oncology platform.
How did the market react to the deal?
Following the announcement, shares for both Tempus AI and Personalis experienced a decline.
What is the value of the deal?
Reports vary, with some sources citing a $1.5 billion valuation and others reporting $1.7 billion.
Will this trend continue gaining momentum or fade within 24 hours?
Cast your anonymous vote to register reader sentiment on news cycle velocity.
Topics
Related trends
Introducing Fierce Biotech's 2026 Fierce 15
Fierce Biotech’s 2026 ‘Fierce 15’ spotlights a new wave of bold, capital‑rich private biotechs racing toward breakthrough medicines.
David Ellison’s Risky Courtroom Strategy to Save His $81 Billion Warner Deal
David Ellison deploys a high-stakes legal maneuver to salvage an $81 billion media merger.
GM to launch its own in-vehicle AI system later this year
General Motors is developing a proprietary in-vehicle artificial intelligence assistant slated for release later this year.
Apple revenue, profits beat expectations on iPhone, Mac sales
Apple concludes the final quarter of Tim Cook’s tenure with performance metrics that exceeded Wall Street projections.
Commerce Department quietly announces 7 new equity stakes in private companies
The U.S. Department of Commerce has issued letters of intent for $874 million in funding to support semiconductor research and development.
NYSE Parent ICE Agrees to Buy MarketAxess for About $6 Billion
Intercontinental Exchange reaches an agreement to acquire bond platform MarketAxess in a multibillion-dollar transaction.